Learning Objectives:
- Overview of the diagnosis and assessment of immune checkpoint inhibitor (ICI) therapy related adverse events.
- Review current data on risk of immune mediated diarrhea and colitis (IMDC) in patients with cancer and pre-existing IBD after initiating ICI therapy.
- Review optimal workup and management considerations in patients with pre-existing IBD.
Session date:
06/06/2023 - 4:30pm to 5:30pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Dr. Tenzin Choden